Last edition
News about "AC-101 tablets"
Accro Bioscience's AC-101 Enters NMPA Rare Disease Development Pilot Program
Accro Bioscience’s AC-101, a novel selective RIPK2 inhibitor, enters the NMPA CDE Caring Plan-Extension pilot program for rare disease drug development.
AC-101 Tablets | 14/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members